Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatitis C Virus
100%
Chronic Kidney Disease
100%
Hepatitis C Virus Infection
100%
Severe Renal Impairment
100%
Glecaprevir
100%
Pibrentasvir
100%
Sustained Virological Response
80%
Adverse Events
40%
End of Treatment
40%
Previous Treatment
40%
Dialysis
20%
Interferon-α (IFN-α)
20%
Ribavirin
20%
Kidney Disease Progression
20%
Confidence Interval
20%
High Risk
20%
Serious Adverse Events
20%
Cirrhosis
20%
Virological Failure
20%
Liver Disease
20%
End-stage Renal Disease
20%
Response Rate
20%
Pruritus
20%
Treatment Efficacy
20%
Nausea
20%
Limited Treatment Options
20%
Phase II Trial
20%
Genotype 1
20%
Genotype 2
20%
Pegylated Interferon
20%
Sofosbuvir
20%
Hepatitis C Virus Genotypes
20%
Chronic Hepatitis C Virus Infection
20%
Genotype 3
20%
Treatment Safety
20%
NS5A Inhibitor
20%
NS3/4A Protease
20%
Genotype 5
20%
Genotype 4
20%
Genotype 6
20%
Virological Relapse
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
100%
Infection
100%
Hepatitis C Virus
100%
Severe Renal Impairment
100%
Glecaprevir
100%
Pibrentasvir
100%
Hepatitis C
83%
Adverse Event
50%
Liver Cirrhosis
16%
Interferon
16%
Liver Disease
16%
End Stage Renal Disease
16%
Chronic Hepatitis C
16%
Pruritus
16%
Ribavirin
16%
Nausea
16%
Sofosbuvir
16%
Hepatitis C Virus Genotype 1
16%
Peginterferon
16%
Nonstructural Protein 5A Inhibitor
16%
Hepacivirin Inhibitor
16%
Diseases
16%